Orexigen Therapeutics Company Profile (NASDAQ:OREX)

Analyst Ratings

Consensus Ratings for Orexigen Therapeutics (NASDAQ:OREX) (?)
Ratings Breakdown: 1 Sell Rating(s), 7 Hold Rating(s)
Consensus Rating:Hold (Score: 1.88)
Consensus Price Target: $2.67 (22.25% downside)

Analysts' Ratings History for Orexigen Therapeutics (NASDAQ:OREX)
Show:
DateFirmActionRatingPrice TargetActions
3/16/2016Leerink SwannLower Price TargetMarket Perform$2.00 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$5.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$5.00 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2015WallachBeth CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/12/2015Bank of America Corp.Reiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Wells Fargo & Co.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Credit Suisse Group AGInitiated CoverageOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Orexigen Therapeutics (NASDAQ:OREX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2016Q116($0.17)($0.15)$7.78 million$5.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2016Q415($0.08)($0.12)$14.07 million$4.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.16)($0.09)$12.17 million$10.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.17)($0.18)$4.92 million$5.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.16)($0.14)$7.28 million$4.36 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q3($0.13)$0.09$8.93 million$30.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.21)($0.21)$1.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q1($0.20)($0.23)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q4($0.19)($0.21)$900.00 million$857.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.18)($0.19)$0.80 million$0.86 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.19)($0.19)$0.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2013Q4 2012($0.44)($0.41)$0.91 million$0.86 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.30)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Orexigen Therapeutics (NASDAQ:OREX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.09)($0.09)($0.09)
Q2 20162($0.14)($0.10)($0.12)
Q3 20162($0.18)($0.10)($0.14)
Q4 20162($0.15)($0.11)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Orexigen Therapeutics (NASDAQ:OREX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Orexigen Therapeutics (NASDAQ:OREX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/2/2014Heather D TurnerSVPSell22,643$6.00$135,858.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Heather D TurnerSVPSell31,388$5.83$182,992.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Louis C BockDirectorBuy1,325$5.58$7,393.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Louis C BockDirectorBuy27,052$5.57$150,679.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Heather D TurnerVPSell300,000$4.47$1,341,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Joseph P HaganVPBuy5,000$4.69$23,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Michael NarachiCEOBuy50,000$4.78$239,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2013Joseph P HaganInsiderSell12,000$7.80$93,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/26/2013Joseph P HaganInsiderSell10,000$7.40$74,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2013Preston KlassenSVPSell71,229$7.16$509,999.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Joseph P HaganInsiderSell28,000$7.00$196,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Preston KlassenSVPSell28,771$7.21$207,438.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2013Mark D BoothInsiderSell22,315$6.67$148,841.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Orexigen Therapeutics (NASDAQ:OREX)
DateHeadline
07/22/16 05:32 PMOrexigen Therapeutics Inc. (OREX) Hits New 52-week Low During ... - Equities.com
07/22/16 08:37 AMOrexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on …
07/21/16 03:10 PMOrexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on August 4, 2016 - [PR Newswire] - SAN DIEGO, July 21, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the second quarter 2016 on Thursday, August 4 th after the market closes. ...
07/21/16 08:33 AMOrexigen Therapeutics, Inc. (NASDAQ:OREX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 08:33 AMStock Moving Lower for the Month; Investor Update on Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Engelwood Daily
07/21/16 08:33 AMOrexigen Therapeutics, Inc. (NASDAQ:OREX) Current Analyst Ratings - Fiscal Standard
07/21/16 08:33 AMOrexigen Therapeutics, Inc. (NASDAQ:OREX) Fundamental Star Rating Report - CML News
07/19/16 05:49 PMZafgen to scrap lead obesity drug, shares slide
07/19/16 11:57 AMETF’s with exposure to Orexigen Therapeutics, Inc. : July 19, 2016 -
07/19/16 06:52 AMIs $6 Price Target Attainable For Orexigen Therapeutics, Inc. (NASDAQ:OREX)? - Investor Newswire
07/19/16 06:52 AMOrexigen Therapeutics, Inc Has Another Bullish Trade, Biotechnology Value Fund L P Bought Stake! - Consumer Eagle
07/18/16 11:05 AMAre Analysts Bearish Orexigen Therapeutics, Inc. (NASDAQ:OREX) After Last Week? - Consumer Eagle
07/18/16 11:05 AMOrexigen Therapeutics, Inc. (NASDAQ:OREX) Wall Street Analyst Recommendation Outlook - TGP
07/16/16 08:57 AMShares Experiencing a Downtrend: Orexigen Therapeutics, Inc. (NASDAQ:OREX) - TGP
07/13/16 06:01 PMAnalyst's Overview of Two Stocks: Shire plc (NASDAQ:SHPG) , Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Street Updates
07/13/16 06:01 PMOrexigen Therapeutics, Inc. (NASDAQ:OREX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 08:36 AMOrexigen Therapeutics Inc. (OREX) Drops 10.11% on July 11 - Equities.com
07/12/16 05:55 PMCompany Shares of Orexigen Therapeutics (NASDAQ:OREX) Drops by -0.8% - TheFounders Daily
07/12/16 05:55 PMStrong Sell Calls For Orexigen Therapeutics, Inc. (NASDAQ:OREX) At 0 - Investor Newswire
07/12/16 05:55 PMOrexigen Therapeutics, Inc. (NASDAQ:OREX) Updated Price Targets - FTSE News
07/12/16 06:03 AMSplits Calendar: Orexigen Therapeutics splits before market open today (1:10 ratio) -
07/11/16 05:08 AMOREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of -
07/10/16 09:49 AMOrexigen Therapeutics Announces Stockholder Approval of All Proposals at 2016 Annual Meeting and Reverse Stock ... - Yahoo Finance
07/10/16 09:49 AMOrexigen To Do 1 For 10 Reverse Split - Seeking Alpha
07/09/16 03:02 PM4:02 pm Orexigen Therapeutics announces 1:10 reverse stock split; expects to begin trading on a post-split basis on July 12 -
07/09/16 08:52 AMOrexigen Therapeutics (OREX) Holders Approval of All Proposals Include 1-for-10 Reverse Stock Split
07/08/16 03:21 PMOrexigen Therapeutics Announces Stockholder Approval of All Proposals at 2016 Annual Meeting and Reverse Stock Split - [at noodls] - SAN DIEGO, July 8, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced stockholder approval of all proposals at its 2016 Annual Meeting held earlier today. Orexigen today also announced ...
07/08/16 08:36 AMHC Stocks Reports: DENTSPLY SIRONA Inc (NASDAQ:XRAY), Orexigen Therapeutics, Inc. (NASDAQ:OREX) - share market updates (press release)
07/08/16 08:36 AMOrexigen Therapeutics (OREX) : Analyst Rating Update - TheFounders Daily
07/07/16 08:34 AMCan Orexigen Therapeutics, Inc. (NASDAQ:OREX) Improve on the Earnings Front? - Engelwood Daily
07/07/16 08:34 AMOrexigen Therapeutics Inc (NASDAQ:OREX) Move Down as Institutional Investors' Sentiment Crashes - Engelwood Daily
07/07/16 08:34 AMOrexigen Therapeutics Inc. (OREX) Drops 5.19% on July 05 - Equities.com
07/05/16 05:26 PMOrexigen Therapeutics Inc (NASDAQ:OREX) Sentiment Worsened, Because Downtrend - Engelwood Daily
07/05/16 03:09 PMOREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure -
07/05/16 10:10 AMOrexigen Therapeutics, Inc. (NASDAQ:OREX) Expected to Reach Highs Of $2 - Investor Newswire
07/03/16 05:02 PMNews Roundup: Orexigen Therapeutics, Inc. (NASDAQ:OREX), Servicemaster Global Holdings Inc(NYSE:SERV ... - iStreetWire
06/29/16 08:29 AMCovering the Bases on Orexigen Therapeutics, Inc. (NASDAQ:OREX): Where is the Stock Going? - Press Telegraph
06/29/16 08:29 AMStrong Sell Calls Recommendations For Orexigen Therapeutics, Inc. (NASDAQ:OREX) At 0 - Investor Newswire
06/28/16 05:36 PMBMS' Opdivo gets 'breakthrough' badge for bladder cancer
06/27/16 09:50 AMOrexigen Therapeutics : Analysts View on Drug Manufacturers - Other Equities - Endo Intl., Teva Pharma, Synergy Pharma, and Orexigen Therapeutics
06/25/16 09:24 AMAnalyst's Stocks Rating Activity: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) , Orexigen Therapeutics, Inc ... - Street Updates
06/23/16 06:13 PMRecently Issued Stock Ratings For Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Fiscal Standard
06/21/16 10:03 AMOrexigen - Contrave Sales Present Troubling Data - Seeking Alpha
06/20/16 05:28 PMThis Weeks Broker Views For Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Fiscal Standard
06/20/16 05:28 PMStrong Buy Calls Count For Orexigen Therapeutics, Inc. (NASDAQ:OREX) At 0 - Investor Newswire
06/20/16 07:17 AMCompany Shares of Orexigen Therapeutics Drops by -0.13% - Trade Calls
06/17/16 08:27 AMRecent Trading Updates: Orexigen Therapeutics, Inc. (NASDAQ:OREX) , Stryker Corporation (NYSE:SYK) - Street Updates
06/16/16 05:54 PMOrexigen Therapeutics : Reports Favorable Markman Ruling in Contrave® Patent Litigation
06/15/16 05:38 PMEarnings in Focus: DENTSPLY International Inc. (NASDAQ:XRAY), Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Beacon Chronicle
06/14/16 05:25 PMPrice Target by Brokers: Orexigen Therapeutics, Inc. (NASDAQ:OREX), TOTAL S.A. (NYSE:TOT) - Beacon Chronicle

Social

About Orexigen Therapeutics

Orexigen Therapeutics logoOrexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OREX
  • CUSIP: 68616410
Key Metrics:
  • Previous Close: $3.43
  • 50 Day Moving Average: $4.3474
  • 200 Day Moving Average: $7.8530
  • P/E Ratio: N/A
  • P/E Growth: 0.0100
  • Market Cap: $49.49M
  • Beta: 2.09
  • Current Year EPS Consensus Estimate: $-7.03 EPS
  • Next Year EPS Consensus Estimate: $-5.85 EPS
Additional Links:
Orexigen Therapeutics (NASDAQ:OREX) Chart for Tuesday, July, 26, 2016